recombinant cd40lg (Novoprotein)
Structured Review

Recombinant Cd40lg, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+cd40lg/pmc12500530-97-1-3?v=Novoprotein
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation"
Article Title: CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease ‐ A Bioinformatic Analysis With Clinical Validation
Journal: Health Science Reports
doi: 10.1002/hsr2.71318
Figure Legend Snippet: Comparison of the expression of genes in RA and RA synovial tissues. (A) There was no difference in CXCL 8 gene expression between RA and OA patients ( p = 0.097). (B) The CD40LG gene expression was higher in RA patients than in OA patients ( p = 0.002). (C) The ITGAX gene expression was higher in RA patients than in OA patients( p = 0.025). (D) There was no difference in IL6 gene expression between RA and OA patients( p = 0.687). (E)The PTPRC gene expression was higher in RA patients than in OA patients( p = 0.003). * p < 0.05; ** p < 0.01.
Techniques Used: Comparison, Expressing, Gene Expression
Figure Legend Snippet: Receiver operating characteristic (ROC) curve of the 5 specifically expressed hub genes. (A) ROC curves for CXCL8. (B) ROC curves for CD40LG. (C) ROC curves for PTPRC. (D) ROC curves for IL6. (E) ROC curves for ITGAX. (F) 5 genes ROC summary.
Techniques Used:
Figure Legend Snippet: Comparison of the relevant antibody levels in the serum of different patients. (A) Comparison of OD values of serum CD40LG, ITGAX and PTPRC in RA, OA, and the HC group. (B) ROC curve of CD40LG in RA patients. (C) Higher serum CD40LG antibody levels in RA patients with combined bone destruction and ILD. ns: no significant difference. * p < 0.05; **** p < 0.0001. ROC, receiver operating characteristic.
Techniques Used: Comparison
Figure Legend Snippet: Molecular docking 3D diagram of key targets and small molecule drugs. (A) CD40LG‐emetine complex, with binding energy of −7.1 kcal/mol. (B) CD40LG‐oligomycin complex, with binding energy of −7.2 kcal/mol. (C) CD40LG‐cromoglicic acid complex, with binding energy of −7.9 kcal/mol. (D) ITGAX‐sulfinpyrazone complex, with binding energy of −7.2 kcal/mol. (E) PTPRC‐oligomycin complex, with binding energy of −8.5 kcal/mol. (F) PTPRC‐buspirone complex, with binding energy of −7.0 kcal/mol. (G) PTPRC‐chlorogenic acid complex, with binding energy of −7.2 kcal/mol.
Techniques Used: Binding Assay